SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-198105
Filing Date
2022-07-20
Accepted
2022-07-20 16:08:56
Documents
12
Period of Report
2022-07-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K d306766d8k.htm   iXBRL 8-K 31301
  Complete submission text file 0001193125-22-198105.txt   158731

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA verv-20220718.xsd EX-101.SCH 2858
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20220718_lab.xml EX-101.LAB 18739
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20220718_pre.xml EX-101.PRE 11709
6 EXTRACTED XBRL INSTANCE DOCUMENT d306766d8k_htm.xml XML 3473
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 221094319
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences